Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in CRSwNP (SINUS-M52)
NCT05049122Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Sanofi. Started Oct 2021; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05049122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05049122.